Veer Bhavnagri Net Worth & Insider Trades

Veer Bhavnagri - General Counsel, Allogene Therapeutics, Inc

As of March 16, 2023

What is Veer Bhavnagri's Net Worth?

The current estimated net worth of Allogene Therapeutics, Inc's General Counsel, Veer Bhavnagri, is estimated to be about $7.2M . Veer Bhavnagri owns about 577,677 units of Allogene Therapeutics, Inc common stock. In the last 3 years at Allogene Therapeutics, Inc, Veer Bhavnagri has sold an estimated value of $5.35M worth.

What is Veer Bhavnagri's Past Insider Trading?

Veer Bhavnagri's largest purchase order was 25,000 units , worth over $56.75K on October 2, 2020. Veer Bhavnagri's largest sale order was 31,553 units , worth over $1.16M on August 5, 2020. In total, Veer Bhavnagri has made about 20 transactions over 3 years of their time at Allogene Therapeutics, Inc. Veer Bhavnagri usually trades in March, with the busiest year in 2021. The most recent transaction was a sale order of 3,000 units , worth over $20.55K on February 14, 2023.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Veer Bhavnagri

Date Range: All Time
Price per Share
Filing Date
No matching records found


Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What was Veer Bhavnagri's Salary in 2020?

As General Counsel of Allogene Therapeutics, Inc, Veer Bhavnagri has a total base salary of $425,000 . Veer Bhavnagri received compensation valued at about $2,396,328 in 2020 after becoming General Counsel. The vast majority of their compensation came in the form of stock awards of $537,490 , option awards of $1,211,953 , other earnings, plans or compensations of $212,500 , and other compensation of $9,385 .

What is Veer Bhavnagri's' Mailing Address?

  • Mailing address is C/o Allogene Therapeutics, Inc. 210 E. Grand Avenue South San Francisco CA 94080 CA

Allogene Therapeutics, Inc Executive Compensation

Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
David Chang, M.D., Ph.D. 2020 $675,000 - - $6,550,535 $506,250 $83,256 $7,815,041
David Chang, M.D., Ph.D. 2019 $600,000 - $4,651,970 $5,327,140 $363,000 $250,000 $11,192,110
David Chang, M.D., Ph.D. 2018 $362,413 - $8,948,152 $3,070,331 $217,641 $250,000 $12,848,537
Eric Schmidt, Ph.D. 2020 $440,000 - $561,176 $1,262,643 $220,000 - $2,483,819
Eric Schmidt, Ph.D. 2019 $425,000 - $1,328,366 $1,519,700 $187,000 - $3,460,066
Eric Schmidt, Ph.D. 2018 $201,232 - - $2,299,658 $88,099 - $2,588,989
Rafael Amado, M.D. 2020 $510,000 $75,000 $561,176 $1,262,643 $255,000 - $2,663,819
Rafael Amado, M.D. 2019 $145,833 - $4,249,976 $2,759,623 $71,726 $225,000 $7,452,158
Alison Moore, Ph.D. 2020 $440,000 - $561,176 $1,262,643 $220,000 - $2,483,819
Alison Moore, Ph.D. 2019 $425,000 - $996,275 $1,519,700 $187,000 - $3,127,975
Alison Moore, Ph.D. 2018 $233,265 - - $1,401,225 $102,124 $100,000 $1,836,614
Veer Bhavnagri 2020 $425,000 - $537,490 $1,211,953 $212,500 $9,385 $2,396,328
No matching records found


What are Allogene Therapeutics, Inc's Past Insider Trades?

Allogene Therapeutics, Inc's most recent insider trade came on August 9, 2023 by Stephen Mayo who sold 10,000 units worth $42.85K . In the last 5 years, insiders at Allogene Therapeutics, Inc have sold an estimated value of $153.14M and bought an estimated value of $33.14M worth of shares. Insider trading is most common in March, with the busiest year in 2020. The most active traders at the company are David Chang, President and CEO,  Veer Bhavnagri, General Counsel,  and Alison Moore, Chief Technical Officer .

Allogene Therapeutics, Inc. Insider Trades

Date Range: All Time
Insider Names
Price per Share
Filing Date
No matching records found